Article Text

Download PDFPDF

Oestrogen plus progestin was not effective for long term secondary prevention of coronary heart disease in postmenopausal women
Free

Statistics from Altmetric.com


 
 QUESTION: In postmenopausal women with established coronary heart disease (CHD), does oestrogen plus progestin reduce the risks of CHD events after 6.8 years of follow up?

Design

Randomised (allocation concealed*), placebo controlled trial. The study was blinded (patients, investigators, and outcome assessors)* for the initial mean 4.1 years of follow up and unblinded* for the subsequent mean 2.7 years of follow up (the latter 2.7 years was the HERS II study).

Setting

20 US outpatient and community centres.

Patients

2763 postmenopausal women <80 years of age (mean age 67 y) with established CHD who had not had a hysterectomy. Of those alive at 4.1 years (n=2510), follow up was 84% at 6.8 years.

Intervention

Women were allocated to conjugated oestrogen, 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n=1380), or placebo (n=1383) for 4.1 years. In the subsequent 2.7 years (during HERS II), 1156 women in the oestrogen plus progestin group and 1165 women in the placebo group continued follow …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.